Medical / Clinical Discussions, page-291

Just had my check-up with the Haematologist / Oncologist. I am more reliant on BTK inhibitors, so he had not much to say on FTO and RAC. He did take down the name of RACE .

Discuss normal treatment, inhibitors and CAR-T treatment. Some of my notes -
1. One will not work for all, if a silver bullet is found, not many will be able to afford it.
2. Treatments work inline 1,2, 3. One drug will fail, and then you move on to the next. The order they occur in based on performance/price. So a fancy new drug may only be 3rd in line as they will try the cheaper, but still effective options 1st.
3. CAR-T treatments will never stand on its own. Will always have to use with something.

So, in my opinion, the use of bisantrene will vary amongst the different cancers. But it appears useful for a LOT of cancers.

Ibrutinib a BTK inhibitor, which is used for rare blood cancers (small market), but was sold at buy out for $21billion (think US $) in 2015.

I acknowledge most of this is known to you—just a refresher.